we are pursuing drugs for some of cancer's most elusive targets

In many disease areas biology has identified the most compelling drug targets.  The vast majority of these targets are elusive to drug discovery for two primary reasons:1. there are no quality ligands for the target,  and 2. there is a limited understanding of the pharmacology (how hard, how long) required to effectively modulate the target. Our mission starts at the nexus of target biology and ligand discovery with two purpose-built platforms

Our biology engine is powered by small molecule control of chimeric proteins, yielding details on the depth and duration of target modulation needed to drive pharmacology.

We use insights from INFINI-T to match target to small molecule modality and guide the optimization of leads by medicinal chemistry toward effective therapeutics for patients. 

Our ligand discovery engine is powered by a diverse library of covalent fragments that extends beyond cysteine and can address all ligandable amino acids.

We use protein structure and computation to optimize covalent hits into leads where the small molecule modality is matched to target biology.